Print

Print


Stem cell patent fight gets personal
Challenge is 'demeaning,' foundation head declares
By KATHLEEN GALLAGHER
[log in to unmask]
Posted: Aug. 31, 2007
Madison - When University of Wisconsin-Madison scientist James Thomson
staked his claim in 1998 as the first researcher to isolate and grow human
embryonic stem cells, he set on fire an emerging area of science that many
believe has potential to cure some of the world's most difficult diseases.
Photo/Tom Lynn
University of Wisconsin University of Wisconsin professor and researcher
James Thomson stands next to a photograph of a stem cell.

Backed by the Wisconsin Alumni Research Foundation, Thompson also set in
motion a patent skirmish that heated up last year when two groups asked the
U.S. Patent and Trademark Office to examine the validity of WARF's three key
embryonic stem cell patents.
WARF Managing Director Carl Gulbrandsen discussed the patent fight during an
interview last week in his 13th-floor office on the UW-Madison campus.
The groups challenging the WARF patents - the Foundation for Taxpayer and
Consumer Rights in Santa Monica, Calif., and the Public Patent Foundation in
New York - have argued that any good scientist with access to embryos and
funding could have done what Thomson did.
"On one hand, they say he deserves all these accolades. On the other hand,
they say anyone could have done it. That's demeaning to him - that's what
really gets my dander up," Gulbrandsen said. "These guys ought to be
embarrassed - no, ashamed - about the way they've dealt with Thomson."
WARF started patenting Thomson's work in 1995, when it filed for rights to
embryonic stem cells in all primates.
The federal government didn't fund work with embryonic stem cells, but other
funding and embryos were not out of reach of scientists at big research
centers, Gulbrandsen said.
"If it was so easy, why would the Israelis have provided embryos to Jamie
Thomson? Why not just do (the research) themselves?" Gulbrandsen asked.
WARF proceeded carefully with patenting and licensing Thomson's work because
of its significance and because of the moral and political issues it raises
for people opposed to research using human embryos, he said.
"We live in a state that's pro-life, so you wanted to make sure everything
you did, you did right," Gulbrandsen said.
WARF's opponents object to the patents, saying Thomson's work was obvious.
But the then-staff scientist didn't even approach WARF about a patent until
at least six months after he cultured human embryonic stem cells because he
wanted to be certain he'd really done it, Gulbrandsen said.
The groups challenging the patents are concerned that WARF's licensing
policies are squelching embryonic stem cell research, said John M. Simpson,
stem cell project director at the Santa Monica consumer watchdog group.
Thomson's work is important, but the patents "overreached," he said.
"I don't see where there's any reason for embarrassment whatsoever in
raising a question about the validity of a patent that was being asserted in
a way that virtually everyone else in the field believed was detrimental to
stem-cell research," Simpson said. "I have no embarrassment we raised the
issue. In fact, I'm proud we did it."
Simpson said WARF has become a "bureaucratic institution" whose agenda is
neither pure scientific inquiry nor technology transfer. "In fact, they have
become much more of an investment vehicle managing a very healthy investment
portfolio rather than a pure technology transfer operation," he said.
WARF has an endowment of about $1.7 billion and gives a portion of its
investment proceeds - $65 million in fiscal 2006 - to the university each
year.
The foundation continues to defend its stem cell patents as part of its
obligation to licensees, Gulbrandsen said. WARF has issued 20 corporate
embryonic stem cell licenses to 17 companies and 1,064 academic licenses to
686 researchers, he said.
Despite the patent challenge, Thomson understands he is on the cutting edge,
Gulbrandsen said.
"He's moving on now to the next big discovery: How do you explain these
cells can be differentiated into any cell in the body."

Rayilyn Brown
Board Member AZNPF
Arizona Chapter National Parkinson's Foundation
[log in to unmask]

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn